Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal Neovascularization
Evaluation of Combined Fine-needle Diathermy and Subconjunctival Bevacizumab Injection in the Treatment of Corneal Neovascularization
HoChiMinh City Eye Hospital
51 participants
Apr 1, 2026
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of combined fine-needle diathermy and subconjunctival Bevacizumab injection in patients with corneal neovascularization. The main questions it aims to answer are: Does combined fine-needle diathermy and subconjunctival Bevacizumab injection promote regression of corneal neovascularization? Is the treatment safe and well tolerated by patients? Participants will: Undergo a baseline evaluation, including assessment of disease duration, ocular history, systemic medical history, and presenting symptoms. Undergo a detailed ophthalmic evaluation, including best-corrected visual acuity, intraocular pressure measurement, slit-lamp examination, corneal photography, and anterior segment optical coherence tomography (AS-OCT). Provide informed consent after explanation of potential risks and benefits of the procedure.
Eligibility
Inclusion Criteria4
- Age over 18 years.
- Diagnosis of corneal neovascularization involving at least one quadrant of the cornea, confirmed by slit-lamp examination.
- Corneal neovascularization is stable with no evidence of progression for at least 4 weeks.
- Agreement to participate in the study and ability to comply with outpatient follow-up requirements
Exclusion Criteria8
- Pregnant or breastfeeding women.
- History of hypersensitivity or allergy to bevacizumab or any component of the study medication.
- Presence of severe systemic disease that would preclude study participation or surgical intervention, including coagulation disorders or uncontrolled cardiovascular disease.
- Active ocular infection or acute conjunctivitis at the time of enrollment.
- Persistent corneal epithelial defect or delayed corneal epithelial healing.
- History of ocular surgery within 3 months before study enrollment.
- Corneal neovascularization associated with uncontrolled secondary glaucoma.
- Inability or unwillingness to comply with study treatment or follow-up visits.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Fine-needle diathermy is performed under an operating microscope using a 10-0 nylon needle and low-power monopolar diathermy to occlude corneal neovessels.
Bevacizumab 2.5 mg/0.1 mL is administered by subconjunctival injection adjacent to the treated corneal neovessels immediately after fine-needle diathermy.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07642960